MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

MDT

86.65

+0.25%↑

114.12

-0.89%↓

VEEV

172.32

-0.47%↓

HQY

81.24

-2.59%↓

PHR.US

9.19

+2.91%↑

Kodu・Aktsiate loetelu・VolitionRX Ltd

VolitionRX Ltd

Avatud

0.16 -5.88

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.14

Max

0.17

Põhinäitajad
By Trading Economics
Sissetulek	936K -5.4M
Müük	221K 627K
Kasumimarginaal	-857.414
Töötajad	75
EBITDA	1.3M -4.2M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+1076.47% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	14. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-21M 26M
Eelmine avamishind	6.04
Eelmine sulgemishind	0.16

VolitionRX Ltd Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. apr 2026, 23:17 UTC

Tulu

Samsung Forecasts Record First-Quarter Operating Profit

6. apr 2026, 23:00 UTC

Kuumad aktsiad

Stocks to Watch: Health Insurers, Mawson, Owlet

6. apr 2026, 22:13 UTC

Suurimad hinnamuutused turgudel

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6. apr 2026, 21:46 UTC

Omandamised, ülevõtmised, äriostud

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6. apr 2026, 17:09 UTC

Suurimad hinnamuutused turgudel

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6. apr 2026, 16:56 UTC

Uudisväärsed sündmused

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6. apr 2026, 14:47 UTC

Suurimad hinnamuutused turgudel

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6. apr 2026, 23:58 UTC

Market Talk

Uudisväärsed sündmused

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6. apr 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6. apr 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6. apr 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6. apr 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6. apr 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6. apr 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6. apr 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. apr 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. apr 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6. apr 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6. apr 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6. apr 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6. apr 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6. apr 2026, 18:36 UTC

Omandamised, ülevõtmised, äriostud

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. apr 2026, 17:59 UTC

Market Talk

Uudisväärsed sündmused

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6. apr 2026, 17:13 UTC

Omandamised, ülevõtmised, äriostud

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. apr 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6. apr 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. apr 2026, 14:59 UTC

Tulu

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Võrdlus sarnastega

Hinnamuutus

VolitionRX Ltd Prognoos

Hinnasiht

By TipRanks

1076.47% tõus

12 kuu keskmine prognoos

Keskmine 2 USD 1076.47%

Kõrge 3 USD

Madal 1 USD

Põhineb 2 Wall Streeti analüütiku instrumendi VolitionRX Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi VolitionRX Ltd aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.